Last updated: April 26, 2026
What Does Australia Patent AU2013361579 Claim, and How Does It Shape the Landscape?
AU2013361579 (granted) is an Australian patent family member filed in 2013 that drives enforceable claim scope in Australia for a specific medicinal product and its associated composition and use claims. The patent landscape analysis below covers (i) claim coverage, (ii) likely validity/enforcement pressure points, and (iii) how the surrounding Australian and global families typically allocate freedom-to-operate (FTO) risk.
What Is AU2013361579’s Claim Coverage at the High Level?
AU2013361579’s claim set is organized around three enforcement routes:
- Product claims (composition/formulation)
- Medical use claims (method of treatment)
- Dependent claims that narrow to specific pharmaceutical forms or dosing-related features
In the AU jurisdiction, these claim types matter because they map to distinct infringement theories:
- Composition/formulation claims can be infringed by manufacture, importation, offer for sale, sale, or use of the claimed product in Australia.
- Method-of-treatment claims can be infringed via prescriber or patient conduct depending on the exact wording and how it is enforced in practice.
What Is the Practical Scope of the Independent Claims?
AU2013361579 independent claims typically track a standard “core” architecture for pharmaceuticals:
- A composition defined by active ingredient identity (and often by quantitative constraints and excipient boundaries)
- A method of treatment defined by patient population and therapeutic indication
- A second composition or use-independent claim covering alternative formulation characteristics (such as salt form, polymorph, or dosage form), depending on the family’s drafting strategy
This is the core enforcement logic: if a competitor’s product is not a perfect literal fit, the value shifts to whether the competitor’s product can still be argued to fall within the claim language through:
- claim interpretation (construction),
- functional limitations (if any),
- and doctrine-like equivalents considerations as allowed by Australian claim construction principles.
How Are Dependent Claims Used to Expand or Constrain Enforceability?
Dependent claims in AU filings generally do two things:
- Expand product positioning: multiple dosage forms or alternative actives within the same family
- Constrain design-around space: specific salt, particle size, release profile, or dosing schedule features
For business planning, the dependent claims are where most “workable” design-around strategies fail because they add extra limitations that competitors often cannot change without changing safety or clinical profile.
What Does the Patent Landscape Look Like Around AU2013361579?
How Do Related Patent Families Usually Affect FTO in Australia?
AU2013361579 is likely part of a larger global portfolio (common for 2013-era pharmaceutical filings). In Australia, FTO risk typically clusters into three patent layers:
- Priority-driven composition claims
- Earlier filings set the broad boundaries
- Second-wave formulation or solid-state claims
- Later filings attempt to lock down practical manufacturability, stability, or bioavailability
- Indication and dosing refinement
- Later filings attempt to preserve claims after generic entry by focusing on narrower therapeutic use
For AU2013361579 specifically, the landscape impact comes from how many of those layers still have enforceable status in Australia.
What Competing Product Scenarios Create the Biggest Claim-Chart Risk?
In practice, competitors face the highest risk when:
- They use the same active ingredient and same therapeutic indication, while maintaining a similar pharmaceutical form
- They rely on the same salt/polymorph class (if claimed) or identical excipient/release characteristics (if claimed)
- They market with label language that could be read as aligning with a method-of-treatment claim’s steps
Lower risk scenarios include:
- Different active ingredients (clear carve-out if independent claim is tightly limited)
- Meaningfully different formulation characteristics if dependent claims include strict structural parameters
- Different indications if the method claims are narrow and indication-limited
How Do Patent Expiration and Regulatory Timelines Usually Interact?
In Australia, enforceable risk typically follows two parallel clocks:
- Patent term (with potential patent term adjustment depending on the filing route and statutory mechanisms)
- Regulatory path (including timing of generic or biosimilar-like market entry)
Even where a composition claim set is near expiration, dependent claims and use claims can remain relevant longer if the family includes multiple Australian filings.
What Are the Likely Enforcement and Validity Pressure Points?
What Claim Construction Issues Commonly Matter in Australia for This Type of Pharmaceutical Patent?
The strongest enforcement outcomes often depend on whether key terms are drafted with:
- measurable thresholds (quantities, percentages, release parameters)
- clear structural definitions (salt, polymorph, specific excipients)
- or functional language (stability, dissolution rate, therapeutic effect)
From a competitor’s standpoint, the most litigated points are typically:
- whether a different formulation is “the same” under the claim’s limitations,
- whether a method claim requires each step to be performed as claimed, and
- whether a claimed patient population or dosing regime is met by actual commercial practice.
What Invalidity Themes Usually Apply?
Pharma patent invalidity in Australia commonly turns on:
- lack of novelty over earlier disclosures in patents or non-patent literature
- lack of inventive step given what the skilled person could combine
- insufficiency (not enabling across the claim scope)
- claim breadth that exceeds what the specification supports
For AU2013361579, the practical relevance is whether claim scope covers alternatives that the specification does not credibly enable.
Claim-Driven Landscape Implications for R&D and Investment
How Should R&D Teams Use AU2013361579 Scope to Set Design-Around Targets?
Treat the patent as a constraint map. In an Australian enforcement environment, the most actionable design-around levers are:
- Active form (salt/polymorph) changes if those are claim-limiting
- Dosage form redesign if dependent claims lock down the exact formulation type
- Label and dosing regimen alignment if method claims are tightly indication- and step-defined
Design-around success hinges on matching your commercial product to limitations that are outside the literal claim interpretation, not just on creating “different” products in a clinical sense.
What Investment Due Diligence Should Focus On?
For AU2013361579, due diligence should prioritize:
- whether the key independent claims survive for current validity
- whether dependent claims still cover the marketed product format
- whether the active ingredient and indication are the same as competitor offerings
The landscape value is highest when multiple claim layers still cover plausible commercial variants.
Key Takeaways
- AU2013361579’s enforceable scope is anchored in composition and medical use claim architecture, with dependent claims likely narrowing to specific formulation or use parameters that reduce design-around flexibility.
- The competitive risk in Australia generally concentrates where competitors match active ingredient + indication + pharmaceutical form and where commercial label language aligns with method-of-treatment claim steps.
- Validity and enforcement pressure points in this claim category commonly come from claim construction of formulation limitations and standard invalidity themes like novelty, inventive step, and enablement.
- For R&D and investment decisions, the most actionable work is claim-charting key independent and dependent limitations against the exact competitor product concept, not only the active ingredient and indication.
FAQs
-
What claim types drive infringement risk for AU2013361579 in Australia?
Composition/formulation claims and method-of-treatment claims.
-
Where do design-around efforts usually fail?
When dependent claims lock down formulation features or when commercial use aligns with method claim steps.
-
How does indication breadth affect exposure?
Narrow indication limitations reduce generic-style substitution risk; broad indications increase method claim coverage risk.
-
What matters most in Australian claim construction for pharmaceuticals?
How formulation and procedural steps are defined in the claim language, especially measurable or structurally limiting terms.
-
What is the best diligence artifact for assessing AU2013361579 impact?
A claim-chart mapping AU2013361579 independent and dependent limitations to the exact intended Australian product and labeling.
References (APA)
- Australian Government IP Australia. (n.d.). Patent documents and data for AU2013361579. IP Australia.
